Compare Natera Inc. Common Stock (NTRA) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Starbucks Corp — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Starbucks Corp trades at $93.36 (market cap $104.88B). The key difference: Starbucks Corp is the larger of the two by market cap, and Starbucks Corp pays a 2.74% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Starbucks Corp for 190 Days on average.
| NTRA | SBUX | |
|---|---|---|
Market Cap | $57.03B | $104.88B |
Volume | 1,131,157 | 9,749,448 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $108.55 |
52-Week Low | $179.42 | $79.60 |
Typical Hold Time | 0 Days | 190 Days |
Enterprise Value | $56.18B | $123.70B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SBUX trades at $93.25, up 1.05% on the day, amid a bearish technical signal and mixed fundamentals. Recent earnings show beats in Q1 and Q2 2026 but a miss in Q4 2025, with net income margin at 5.17%. The company is undergoing a strategic reset, closing 250 North American stores to optimize its portfolio, while facing headwinds from labor relations and geopolitical pressures in China.
The stock presents a cautious outlook with a high P/E of 53.18 suggesting premium valuation, yet analyst consensus targets $115.50 imply upside. Key risks include execution of store closures, competitive pressures, and macroeconomic sensitivity. Investor sentiment is divided, balancing restructuring potential against near-term operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
